Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies

Autor: Linton, Kim, Collins, Graham P., Forconi, Francesco, Shah, Nirav N., Dixit, Karan, Munir, Talha, Omer, Zulfa, El-Sharkawi, Dima, Doorduijn, Jeanette, Alencar, Alvaro, McKay, Pam, Riches, John, Gleeson, Mary, Lewis, David, Winter, Allison, Injac, Sarah, Shih, Ted, Nandakumar, Srinand, Tan, May, Cherala, Ganesh, Meredith, Erin, Danilov, Alexey
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S184-S184
Databáze: ScienceDirect
Externí odkaz: